Replexa+
A Device for Relieving Pain
An FDA cleared device using proven thermal shortwave diathermy technology to help veterans and active military attain consistent, positive outcomes
Who is Replexa+ For?
Replexa+ is a prescription-only device available for veterans and active military to relieve pain where other therapies, medications, or procedures have not achieved the level of desired outcome
What is Replexa+?
Replexa+ is a standalone therapy harnessing the therapeutic effects of thermal shortwave diathermy
Two applicators can effectively target multiple treatment areas and offer comfortable placement options
What are the FDA Indications for Use?
Relieving Pain
Reducing Muscle Spasm
Increasing range of motion of contracted joints using heat and stretch techniques
Increasing blood flow to tissues in the treatment area
Device Operation
One-touch control to Start/Stop treatment
LCD color screen shows treatment progress and time remaining
A chime will signal the end of the treatment session and treatment will automatically stop
Replexa+ device comes with two applicators that may be used together or independently on a variety of treatment locations
Where to Use It
What to Expect
Replexa+ thermal shortwave diathermy is applied in short, high-energy pulses
As a result, the depth of penetration is increased while relieving pain, increasing blood flow to tissues in the treatment area, reducing muscle spasm, and increasing range of motion of contracted joints in superficial soft and deep tissues with little to no sensation felt on the skin
Technology
Shortwave diathermy (SWD) is a non-invasive therapeutic application of oscillating, electromagnetic energy
Depending on the device, SWD can be used on soft or hard tissues:
Soft tissues – muscles, tendons, ligaments
Hard tissues – bone
Thermal vs Non-Thermal
Thermal – generates a thermal effect
Non-Thermal – no thermal effect
Pulsed vs Continuous:
Pulsed – delivers energy in pulses
Continuous – continuous energy delivery
Inductive vs Capacitive:
Inductive – primarily magnetic in nature
Capacitive – primarily electro in nature
Types of Shortwave Diathermy
What Type is Replexa+
Replexa+ is:
For soft tissues – targets both superficial and deep tissues such as muscles, tendons, and ligaments
Thermal – generates a thermal effect
Replexa+ common settings are:
Pulsed – delivers energy in pulses operating at 27.12 MHz
Inductive – is primarily magnetic in nature
Why is the Type of SWD Important?
Soft vs Hard Tissue:
Designed to treat soft tissues, the Replexa+ targets pain areas in the superficial soft and deeper tissues such as muscles, tendons, and ligaments
Thermal vs Non-Thermal:
Being FDA classified as thermal, Replexa+ has broader indications for use and provides a thermal benefit to both deep and superficial soft tissues. It can be used as a standalone, primary therapy and is not limited to adjunctive, palliative, or post-operative treatment
Pulsed vs Continuous:
Using pulsed energy, the Replexa+ is able to penetrate deeper while providing a therapeutic thermal effect
Inductive vs Capacitive:
Using an inductive field, the Replexa+ energy is primarily magnetic in nature and effectively targets both superficial soft and deeper tissues such as muscles, tendons, and ligaments
Thermal vs Non-Thermal Summary
The FDA classifies shortwave diathermy into either a thermal or a non-thermal classification. The thermal classification can provide thermal clinical benefits while everything else only provides non-thermal benefits. The FDA has assigns different indications of use for thermal based on its proven safety and efficacy.
Non-thermal Shortwave Diathermy classified devices are indicated for adjunctive use in the palliative treatment of postoperative pain and edema in the superficial soft tissue.
Thermal Shortwave Diathermy classified devices provide a thermal benefit to the superficial soft and deep tissues, are not limited to an adjunctive, palliative, or post-operative treatment, and can be used as a standalone, primary therapy to treat various conditions.
The Replexa+ device is a thermal device with FDA indications for use that include relieving pain, increasing blood flow to tissues in the treatment area, reducing muscle spasm, increasing range of motion of contracted joints using heat and stretch techniques.
Overview of Replexa+
Scientific Research:
Fibroblast cells treated with Replexa+ showed a statistically significant 27% increase in the rate of mitosis over the control (p<0.001)
Positive Outcomes:
96% of patients who consistently used Replexa+ achieved a reduction in pain and/or an improvement in quality of life
84% of plantar fasciitis patients achieved a reduction in pain and/or an improvement in quality of life